Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 19-Nov-24 4:08 PM View:  | Altshuler David EVP, Chief Scientific Officer | Vertex Pharmaceuticals Inc. (VRTX) | 15-Nov-24 | Private Sale (Planned) | 15 | $478.56 | $7,178.40 | (< 1%) 25.83K to 25.81K | |
| 04-Sep-24 4:13 PM View: | Leiden Jeffrey M Executive Chairman Director | Vertex Pharmaceuticals Inc. (VRTX) | 30-Aug-24 | Private Sale (Planned) | 3,784 | $499.00 | $1,888,220.00 | (27%) 14.22K to 10.43K | |
| 04-Sep-24 4:12 PM View: | Bhatia Sangeeta N. Director | Vertex Pharmaceuticals Inc. (VRTX) | 30-Aug-24 | Option Exercise | 646 | $152.74 | $98,670.00 | 15% 4.43K to 5.08K | |
| 04-Sep-24 4:12 PM View: | Bhatia Sangeeta N. Director | Vertex Pharmaceuticals Inc. (VRTX) | 30-Aug-24 | Planned Option Sale | 646 | $500.00 | $323,000.00 | (13%) 5.08K to 4.43K | |
| 12-Aug-24 4:08 PM View: | Bhatia Sangeeta N. Director | Vertex Pharmaceuticals Inc. (VRTX) | 08-Aug-24 | Planned Option Sale | 1,292 | $466.29 | $602,447.00 | (23%) 5.73K to 4.43K | |
| 12-Aug-24 4:08 PM View: | Bhatia Sangeeta N. Director | Vertex Pharmaceuticals Inc. (VRTX) | 08-Aug-24 | Option Exercise | 1,292 | $152.74 | $197,340.00 | 29% 4.43K to 5.73K | |
| 08-Aug-24 4:06 PM View: | Bozic Carmen EVP and CMO | Vertex Pharmaceuticals Inc. (VRTX) | 07-Aug-24 | Private Sale (Planned) | 2,280 | $476.75 | $1,086,990.00 | (9%) 25.54K to 23.26K | |
| 02-Aug-24 4:10 PM View: | Sachs Bruce I Director | Vertex Pharmaceuticals Inc. (VRTX) | 01-Aug-24 | Option Exercise | 5,295 | $125.71 | $665,634.00 | 13% 40.0K to 45.3K | |
| 02-Aug-24 4:10 PM View: | Sachs Bruce I Director | Vertex Pharmaceuticals Inc. (VRTX) | 01-Aug-24 | Planned Option Sale | 5,295 | $508.00 | $2,689,860.00 | (12%) 45.3K to 40.0K | |
| 01-Aug-24 4:17 PM View: | Kewalramani Reshma CEO & President Director | Vertex Pharmaceuticals Inc. (VRTX) | 30-Jul-24 | Private Sale (Planned) | 15,202 | $505.00 | $7,677,010.00 | (14%) 106.17K to 90.97K | |
| 25-Jul-24 4:06 PM View: | Bozic Carmen EVP and CMO | Vertex Pharmaceuticals Inc. (VRTX) | 24-Jul-24 | Private Sale (Planned) | 2,280 | $488.46 | $1,113,690.00 | (8%) 27.82K to 25.54K | |
| 24-Jul-24 4:05 PM View: | Kewalramani Reshma CEO & President Director | Vertex Pharmaceuticals Inc. (VRTX) | 22-Jul-24 | Private Sale (Planned) | 15,202 | $497.00 | $7,555,390.00 | (13%) 121.37K to 106.17K | |
| 12-Jul-24 4:07 PM View: | Bozic Carmen EVP and CMO | Vertex Pharmaceuticals Inc. (VRTX) | 10-Jul-24 | Private Sale (Planned) | 2,280 | $487.34 | $1,111,140.00 | (8%) 30.1K to 27.82K | |
| 28-Jun-24 4:04 PM View: | Bozic Carmen EVP and CMO | Vertex Pharmaceuticals Inc. (VRTX) | 26-Jun-24 | Private Sale (Planned) | 2,280 | $471.72 | $1,075,520.00 | (7%) 32.38K to 30.1K | |
| 13-Jun-24 4:11 PM View: | Bozic Carmen EVP and CMO | Vertex Pharmaceuticals Inc. (VRTX) | 12-Jun-24 | Private Sale (Planned) | 2,280 | $478.00 | $1,089,840.00 | (7%) 34.66K to 32.38K | |
| 13-Jun-24 4:09 PM View: | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Vertex Pharmaceuticals Inc. (VRTX) | 12-Jun-24 | Sale (Planned) | 7,288 | $478.00 | $3,483,660.00 | (31%) 23.26K to 15.97K | |
| 13-Jun-24 4:09 PM View: | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Vertex Pharmaceuticals Inc. (VRTX) | 11-Jun-24 | Payment of Exercise | 6,824 | $481.96 | $3,288,900.00 | (23%) 30.08K to 23.26K | |
| 07-Jun-24 4:07 PM View: | Sachdev Amit EVP Chief Patient & Ext Af Off | Vertex Pharmaceuticals Inc. (VRTX) | 05-Jun-24 | Gift | 4,600 | -- | -- | (7%) 62.77K to 58.17K | |
| 05-Jun-24 4:08 PM View: | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Vertex Pharmaceuticals Inc. (VRTX) | 03-Jun-24 | Private Sale (Planned) | 2,175 | $460.00 | $1,000,500.00 | (4%) 51.27K to 49.1K | |
| 05-Jun-24 4:11 PM View: | Wagner Charles F Jr EVP & Chief Financial Officer | Vertex Pharmaceuticals Inc. (VRTX) | 03-Jun-24 | Private Sale (Planned) | 3,250 | $460.00 | $1,495,000.00 | (6%) 50.39K to 47.14K | |
| 03-Jun-24 4:09 PM View: | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Vertex Pharmaceuticals Inc. (VRTX) | 31-May-24 | Sale (Planned) | 2,250 | $445.00 | $1,001,250.00 | (4%) 53.52K to 51.27K | |
| 03-Jun-24 4:09 PM View: | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Vertex Pharmaceuticals Inc. (VRTX) | 30-May-24 | Private Sale (Planned) | 2,350 | $439.11 | $1,031,910.00 | (4%) 55.87K to 53.52K | |
| 31-May-24 4:19 PM View: | Bozic Carmen EVP and CMO | Vertex Pharmaceuticals Inc. (VRTX) | 29-May-24 | Private Sale (Planned) | 2,280 | $445.56 | $1,015,880.00 | (6%) 36.94K to 34.66K | |
| 30-May-24 4:07 PM View: | Wagner Charles F Jr EVP & Chief Financial Officer | Vertex Pharmaceuticals Inc. (VRTX) | 28-May-24 | Private Sale (Planned) | 3,250 | $454.79 | $1,478,070.00 | (6%) 53.64K to 50.39K | |
| 29-May-24 4:08 PM View: | Kewalramani Reshma CEO & President Director | Vertex Pharmaceuticals Inc. (VRTX) | 24-May-24 | Option Exercise | 1,565 | $187.53 | $293,484.00 | 1% 121.37K to 122.94K | (10%) |
| 29-May-24 4:08 PM View: | Kewalramani Reshma CEO & President Director | Vertex Pharmaceuticals Inc. (VRTX) | 24-May-24 | Planned Private Option Sale | 1,565 | $457.00 | $715,205.00 | (1%) 122.94K to 121.37K | |
| 24-May-24 4:13 PM View: | Sachs Bruce I Director | Vertex Pharmaceuticals Inc. (VRTX) | 22-May-24 | Planned Option Sale | 7,073 | $448.00 | $3,168,700.00 | (15%) 47.07K to 40.0K | |
| 24-May-24 4:13 PM View: | Sachs Bruce I Director | Vertex Pharmaceuticals Inc. (VRTX) | 22-May-24 | Option Exercise | 7,073 | $93.51 | $661,396.00 | 18% 40.0K to 47.07K | |
| 22-May-24 4:21 PM View: | Kewalramani Reshma CEO & President Director | Vertex Pharmaceuticals Inc. (VRTX) | 20-May-24 | Private Sale (Planned) | 15,202 | $447.00 | $6,795,290.00 | (11%) 136.58K to 121.37K | |
| 17-May-24 4:27 PM View: | Sachdev Amit EVP Chief Patient & Ext Af Off | Vertex Pharmaceuticals Inc. (VRTX) | 15-May-24 | Private Sale (Planned) | 32 | $430.93 | $13,789.80 | (< 1%) 62.8K to 62.77K | |
| 17-May-24 4:18 PM View: | Schneider Jennifer Director | Vertex Pharmaceuticals Inc. (VRTX) | 15-May-24 | Grant | 922 | -- | -- | 100% 0 to 0.92K | |
| 17-May-24 4:22 PM View: | Altshuler David EVP, Chief Scientific Officer | Vertex Pharmaceuticals Inc. (VRTX) | 15-May-24 | Private Sale (Planned) | 54 | $430.93 | $23,270.20 | (< 1%) 25.87K to 25.81K | |
| 17-May-24 4:24 PM View: | Arbuckle Stuart A EVP, COO | Vertex Pharmaceuticals Inc. (VRTX) | 15-May-24 | Private Sale (Planned) | 69 | $430.93 | $29,734.20 | (< 1%) 49.9K to 49.83K | |
| 16-May-24 4:12 PM View: | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Vertex Pharmaceuticals Inc. (VRTX) | 14-May-24 | Grant | 14,112 | -- | -- | 88% 15.97K to 30.08K | |
| 03-May-24 4:05 PM View: | Bhatia Sangeeta N. Director | Vertex Pharmaceuticals Inc. (VRTX) | 02-May-24 | Sale (Planned) | 467 | $402.95 | $188,178.00 | (10%) 4.9K to 4.43K | |
| 03-May-24 4:05 PM View: | Bhatia Sangeeta N. Director | Vertex Pharmaceuticals Inc. (VRTX) | 01-May-24 | Grant | 1,001 | -- | -- | 26% 3.9K to 4.9K | |
| 03-May-24 4:23 PM View: | Thornberry Nancy Director | Vertex Pharmaceuticals Inc. (VRTX) | 01-May-24 | Grant | 501 | -- | -- | 44% 1.14K to 1.64K | |
| 03-May-24 4:18 PM View: | McKenzie Diana Director | Vertex Pharmaceuticals Inc. (VRTX) | 01-May-24 | Grant | 1,001 | -- | -- | 36% 2.81K to 3.81K | |
| 03-May-24 4:26 PM View: | Upadhyay Suketu Director | Vertex Pharmaceuticals Inc. (VRTX) | 01-May-24 | Disposition | 1,168 | -- | -- | (31%) 3.73K to 2.56K | |
| 03-May-24 4:18 PM View: | McKenzie Diana Director | Vertex Pharmaceuticals Inc. (VRTX) | 01-May-24 | Disposition | 1,168 | -- | -- | (31%) 3.81K to 2.64K | |
| 03-May-24 4:09 PM View: | Carney Lloyd Director | Vertex Pharmaceuticals Inc. (VRTX) | 01-May-24 | Grant | 1,001 | -- | -- | 19% 5.32K to 6.32K | |
| 03-May-24 4:26 PM View: | Upadhyay Suketu Director | Vertex Pharmaceuticals Inc. (VRTX) | 01-May-24 | Grant | 1,001 | -- | -- | 37% 2.73K to 3.73K | |
| 03-Apr-24 4:02 PM View: | Ambrose Kristen SVP & Chief Accounting Officer | Vertex Pharmaceuticals Inc. (VRTX) | 02-Apr-24 | Sale (Planned) | 240 | $419.00 | $100,560.00 | (3%) 7.74K to 7.5K | |
| 03-Apr-24 4:02 PM View: | Ambrose Kristen SVP & Chief Accounting Officer | Vertex Pharmaceuticals Inc. (VRTX) | 01-Apr-24 | Payment of Exercise | 225 | $418.10 | $94,072.50 | (3%) 7.96K to 7.74K | |
| 27-Feb-24 4:29 PM View: | Ambrose Kristen SVP & Chief Accounting Officer | Vertex Pharmaceuticals Inc. (VRTX) | 26-Feb-24 | Sale (Planned) | 883 | $425.70 | $375,893.00 | (10%) 8.85K to 7.96K | |
| 27-Feb-24 5:02 PM View: | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Vertex Pharmaceuticals Inc. (VRTX) | 26-Feb-24 | Sale (Planned) | 354 | $425.70 | $150,698.00 | (< 1%) 56.16K to 55.8K | |
| 27-Feb-24 4:44 PM View: | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Vertex Pharmaceuticals Inc. (VRTX) | 26-Feb-24 | Sale (Planned) | 883 | $425.70 | $375,893.00 | (5%) 16.86K to 15.97K | |
| 27-Feb-24 4:37 PM View: | Arbuckle Stuart A EVP, COO | Vertex Pharmaceuticals Inc. (VRTX) | 26-Feb-24 | Sale (Planned) | 5,034 | $425.70 | $2,142,970.00 | (9%) 54.87K to 49.83K | |
| 27-Feb-24 4:59 PM View: | Sachdev Amit EVP Chief Patient & Ext Af Off | Vertex Pharmaceuticals Inc. (VRTX) | 26-Feb-24 | Sale (Planned) | 3,004 | $425.70 | $1,278,800.00 | (5%) 65.78K to 62.77K | |
| 27-Feb-24 4:24 PM View: | Altshuler David EVP, Global Research and CSO | Vertex Pharmaceuticals Inc. (VRTX) | 26-Feb-24 | Sale (Planned) | 4,239 | $425.70 | $1,804,540.00 | (14%) 30.05K to 25.81K |
